Stability Testing Medicated Premixes Draft Guidance (VICH GL8(R))
Summary
FDA's Center for Veterinary Medicine has published draft guidance CVM GFI 91 (VICH GL8(R)) on stability testing of medicated premixes, intended as an annex to the parent VICH GL3 guidance. The draft addresses stability data requirements for veterinary medicinal premix products containing new molecular entities, intended for oral administration via incorporation into animal feed. The guidance is open for public comment.
“The guidance primarily addresses the generation of acceptable stability information for submission in Registration Applications for medicated premix drug products containing new molecular entities.”
What changed
This draft guidance annexes VICH GL3 by providing specific stability testing recommendations for medicated premixes — veterinary drug products administered orally through animal feed. It addresses areas where application of the parent guidance may be limited, providing flexibility for scientific and practical considerations specific to these products. The scope covers stability information for registration applications but does not currently cover products manufactured from medicated premixes, or studies related to conditioning, pelleting, segregation, or homogeneity.
Drug manufacturers and pharmaceutical companies developing new veterinary medicinal premix products intended for approval in the EU, Japan, or the United States should review this draft and submit comments. Quality assurance and regulatory affairs teams should identify gaps between current stability protocols and the draft VICH GL8(R) recommendations, particularly where the annex specifies differing requirements from the parent VICH GL3 guidance.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Search for FDA
Guidance Documents
Docket Number: FDA-2021-D-0613 Issued by: Guidance Issuing Office Center for Veterinary Medicine This guidance document is an annex to the parent guidance VICH GL3, “Stability Testing of New Veterinary Drug Substances and Medicinal Products.” It addresses the recommendations for stability testing of new veterinary medicinal Medicated Premix products intended for submission for approval to the European Union, Japan and the United States. The parent guidance (VICH GL3) provides a general indication of the information on product stability generated, but the annex for Medicated Premixes leaves sufficient flexibility to encompass a variety of different practical and scientific considerations that are specific to the characteristics of the drug products being evaluated. Other stability studies which might be important to consider like stability in relation to conditioning and pelleting, segregation and homogeneity studies are not within the scope of this guidance.
The guidance primarily addresses the generation of acceptable stability information for submission in Registration Applications for medicated premix drug products containing new molecular entities. Medicated Premixes are intended for oral administration following incorporation into animal feed. The guidance only pertains to Medicated Premixes, and does not currently seek to cover information required for products manufactured from medicated premixes. Stability studies carried out with a medicated premix should be in line with the parent guidance. However, the application of the parent guidance may be limited in some instances. This guidance therefore describes those areas where there may be differences in the stability data package for medicated premixes.
Submit Comments
Submit Comments Online You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2021-D-0613.
Questions?
Contact Point CVM Center for Veterinary Medicine
Food and Drug Administration
5001 Campus Drive
College Park, MD 20740
AskCVM@fda.hhs.gov (240) 402-7002
- ## Content current as of:
04/21/2026
Regulated Product(s)
- Animal & Veterinary
- Animal Feed
Topic(s)
- VICH
- Chemistry, Manufacturing, and Controls (CMC)
Mentioned entities
Related changes
Get daily alerts for FDA Guidance Documents
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA CVM.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when FDA Guidance Documents publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.